The protection of atorvastatin to myocardium in patients with unstable angina during percutaneous transluminal coronary intervention therapy

Objective To evaluate the protection effect of atorvastatin treatment to myocardium during percutaneous transluminal coronary intervention(PCI) in patients with unstable angina pectoris.Methods One hundred patients with unstable angina were randomized to atorvastatin group,who received atorvastatin 40 mg per day for 3 to 7 days,and control group,who did not receive statin therapy before PCI.All patients were given conventional treatment for coronary artery disease.Serum TnT,CK-MB,and Hs-CRP were checked before and 24 hours after PCI in both groups.All the patients were followed 1 month for major adverse cardiac events.Results The rates of TnT and CK-MB elevation were lower in atorvastatin group than in control group,but no statistical significance(17.6% vs.24.5%,P0.05 and 17.6%vs.32.7%,P0.05,respectively) was found.Seven patients in atorvastatin group and eight patients in control group(13.7% vs.16.3%,P0.05) had ALT elevation,there is no severe adverse reaction in both group.The change of Hs-CRP after PCI in atorvastatin group was similar to that in control group(0.81±3.14 vs.-0.12±1.53,P0.05).During 1 month follow-up,there is no death,myocardial infarction or revascularization in both groups.Conclusion Atorvastatin therapy before PCI has good safety and tolerance,it may lead to potential reduction of myocardial damage during PCI.